| L - Antineoplastic and Immunomodulating Agents | This group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.
|
|
| L04 - Immunosuppressants | Immunosuppressants are defined as agents that completely or partly suppress one or more factors in the immunosystem.
|
|
| L04A - Immunosuppressants | This group comprises immunosuppressants excl. corticosteroids.
| The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.
|
|
| L04AC - Interleukin Inhibitors | Interleukin inhibitors used in asthma are classified in R03DX.
Dupilumab is classified in D11AH.
| The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.
The DDD for daclizumab is based on the treatment of multiple sclerosis.
The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.
|
|
|
